Carvedilol is one of the most effective beta blockers for preventing ventricular tachyarrhythmias in heart failure, but the mechanisms underlying its favorable antiarrhythmic benefits remain unclear. Spontaneous Ca 2+ waves, also called store overloadinduced Ca 2+ release (SOICR), evoke ventricular tachyarrhythmias in individuals with heart failure. Here we show that carvedilol is the only beta blocker tested that effectively suppresses SOICR by directly reducing the open duration of the cardiac ryanodine receptor (RyR2). This unique anti-SOICR activity of carvedilol, combined with its beta-blocking activity, probably contributes to its favorable antiarrhythmic effect. To enable optimal titration of carvedilol's actions as a beta blocker and as a suppressor of SOICR separately, we developed a new SOICR-inhibiting, minimally beta-blocking carvedilol analog, VK-II-86. VK-II-86 prevented stress-induced ventricular tachyarrhythmias in RyR2-mutant mice and did so more effectively when combined with either of the selective beta blockers metoprolol or bisoprolol. Combining SOICR inhibition with optimal beta blockade has the potential to provide antiarrhythmic therapy that can be tailored to individual patients.
Ventricular tachyarrhythmias are a leading cause of sudden death. Over the past 40 years, a variety of pharmacological therapies for ventricular tachyarrhythmias have been developed. In large clinical trials, most antiarrhythmic drugs currently used have little or no survival benefit, and may even be harmful [1] [2] [3] . There is one exception: antagonists of β-adrenergic receptors ('beta blockers') generally reduce ventricular tachyarrhythmias and prevent sudden death. In particular, carvedilol, a nonselective beta blocker with antioxidant and α-adrenergic receptor blocking ('alpha-blocking') activities, is one of the most effective beta blockers in reducing ventricular tachyarrhythmias and mortality in individuals with heart failure [4] [5] [6] [7] . However, the mechanism underlying the favorable antiarrhythmic effect of carvedilol remains unclear 8, 9 . The antioxidant and alpha-blocking activities of carvedilol have been suggested to contribute to its beneficial effects, but the benefits of antioxidants and alpha blockers have not been corroborated by clinical studies 10, 11 . Thus, an unknown carvedilol-specific action is likely to be involved. Identifying this unknown action could have major implications for the understanding and treatment of cardiac arrhythmias and the development of new antiarrhythmic therapies.
Excessive β-adrenergic receptor (β-AR) stimulation can lead to sarcoplasmic reticulum Ca 2+ overload that can trigger spontaneous Ca 2+ waves [12] [13] [14] , also known as SOICR, mediated by RyR2 (refs. 15, 16) . This SOICR can evoke delayed afterdepolarizations (DADs) that can lead to triggered arrhythmias and sudden death [17] [18] [19] [20] [21] [22] [23] . Indeed, SOICR-evoked DADs cause catecholaminergic polymorphic ventricular tachycardia (CPVT), which is associated with naturally occurring RyR2 mutations 15, 16, [24] [25] [26] [27] [28] [29] . SOICR-evoked DADs are also a major cause of ventricular tachyarrhythmias and sudden death in heart failure 12, 13, 30, 31 . Beta blockers suppress β-AR-mediated, stress-induced sarcoplasmic reticulum Ca 2+ overload and its arrhythmogenicity 9, [12] [13] [14] . However, beta blocker effectiveness is limited by drug intolerance and the existence of β-AR-independent causes of Ca 2+ overload (for example, Na + -dependent Ca 2+ overload) 2, 32, 33 .
We propose that carvedilol, in addition to its beta-blocking action, directly suppresses SOICR itself. In two well-established SOICR cell models, we found that carvedilol is the only beta blocker tested that can effectively suppress SOICR. Carvedilol did so by directly altering the function of RyR2, independent of its beta-or alpha-blocking 1 0 0 4 VOLUME 17 | NUMBER 8 | AUGUST 2011 nature medicine or antioxidant activities. Our results suggest that SOICR inhibition combined with optimal beta blockade could be an effective means to treat Ca 2+ -mediated ventricular tachyarrhythmias.
RESULTS

Carvedilol is the only beta blocker that suppresses SOICR
To determine whether carvedilol possesses a unique action on intracellular Ca 2+ handling, we assessed the impact of a number of beta blockers on SOICR in HEK293 cells expressing a SOICR-promoting, CPVT-causing RyR2 mutation (R4496C). Of the 14 beta blockers tested, only carvedilol effectively inhibited SOICR (>95%). All the other beta blockers tested had no impact on SOICR even at relatively high concentrations (30 µM; Fig. 1 ).
To further assess whether the alpha-blocking and antioxidant activities of carvedilol contribute to its unique action, we tested the impact of alpha blockers (prazosin and phentolamine) and antioxidants (N-(2-mercaptopropionyl)-glycine and α-tocopherol) on SOICR. None of these agents significantly altered SOICR (Fig. 1b) . Thus, carvedilol is the only beta blocker that effectively suppresses SOICR, and this effect is independent of its beta-and alpha-blocking and antioxidant activities.
Carvedilol directly modifies the function of RyR2 channel
To test the possibility that carvedilol suppresses SOICR by directly altering the function of RyR2, we assessed the impact of carvedilol on single native RyR2 channels from sarcoplasmic reticulum microsomes fused into lipid bilayers. Carvedilol (1 µM) significantly reduced RyR2 mean open time (P < 0.01) and open probability (P < 0.01), and increased the event frequency (P < 0.01). The mean closed time was not significantly altered by carvedilol (P = 0.10; Fig. 2a ).
We also assessed the impact of carvedilol on single purified recombinant RyR2 channels. Carvedilol (1 µM) significantly reduced their mean open time (P < 0.01) and increased their event frequency (P < 0.05; Fig. 2b ). Carvedilol also reduced intraburst event duration, while increasing intraburst event frequency (P < 0.05; Supplementary Fig. 1 ). Thus, carvedilol consistently reduces the duration and increases the frequency of single RyR2 openings. 
Carvedilol suppresses SOICR in cardiomyocytes
We next determined whether carvedilol can suppress SOICR in cardiomyocytes from mice harboring the SOICR-promoting, CPVT-causing RyR2 mutation, R4496C (Supplementary Fig. 2 ). Line-scan confocal Ca 2+ imaging showed that carvedilol (1 µM) significantly reduced the occurrence and frequency of SOICR (P < 0.05), whereas metoprolol (2 µM) and the vehicle DMSO had no significant effect (Fig. 3a-c) .
The sarcoplasmic reticulum Ca 2+ contents in cardiomyocytes treated with carvedilol, metoprolol or DMSO were not significantly different (Fig. 3d) . We also used epifluorescence single-cell Ca 2+ imaging to determine the impact of carvedilol on SOICR in cardiomyocytes. Carvedilol (1 µM) significantly decreased the occurrence and frequency of SOICR (P < 0.05) in these cells. In contrast, metoprolol (2 µM) or the vehicle DMSO had no significant effect ( Fig. 3e-g ).
We also determined the impact of low concentrations of carvedilol on SOICR. Cardiomyocytes were incubated with 0.3 µM (or 122 ng ml −1 ) carvedilol, which is similar to the peak plasma concentration of carvedilol after dosing in humans (~100 ng ml −1 ) 34, 35 , for 3 h before the induction of SOICR. Cardiomyocytes treated with 0.3 µM carvedilol had a significantly lower occurrence (P < 0.01) and frequency (P < 0.01) of SOICR compared to DMSO-treated cells. The frequency and occurrence of SOICR in cardiomyocytes treated with 0.6 µM metoprolol, 0.6 µM prazosin or 6 µM α-tocopherol did not differ significantly from those in DMSO-treated cells (Fig. 3h,i) . Thus, carvedilol at clinically relevant concentrations suppresses SOICR in cardiomyocytes, independent of its beta-and alpha-blocking and antioxidant activities.
SOICR-inhibiting carvedilol analogs with minimal beta blockade
To individually and optimally titrate SOICR inhibition and beta blockade, we set out to separate the anti-SOICR activity of carvedilol from its beta-blocking effect by generating SOICR-inhibiting carvedilol analogs with minimal beta blockade. To this end, we made several structural modifications to carvedilol (Supplementary Fig. 3) . Whereas carvedilol and metoprolol markedly suppressed the enhanced heart rate induced by isoproterenol in wild-type (WT) mice, one of the analogs, VK-II-86, did not (similarly to the vehicle DMSO; Fig. 4a,b) . Treatment of mice heterozygous for the R4496C mutation with carvedilol or metoprolol for 5 d decreased their heart rate (P < 0.01), but a 5-d VK-II-86 treatment did not (P = 0.18; Fig. 4c) .
Carvedilol, but not VK-II-86, abolished isoproterenol-induced PKA phosphorylation of RyR2 (Supplementary Fig. 4) . Radioligandbinding studies showed that VK-II-86 had a β-AR binding affinity more than three orders of magnitude lower than did carvedilol ( Supplementary Fig. 5 and Supplementary Table 1) . Thus, VK-II-86 lacks the beta-blocking activity of carvedilol and has little impact on heart rate.
Action of VK-II-86 on SOICR and single RyR2 channels
We next assessed the impact of VK-II-86 on SOICR and single RyR2 channels. Like carvedilol, VK-II-86 completely abolished SOICR in HEK293 cells (P < 0.01; Fig. 4d and Supplementary Fig. 4) . VK-II-86 (1 µM) pretreatment of cardiomyocytes for 30 min significantly reduced the occurrence (P < 0.01) and frequency (P < 0.01) of SOICR in both confocal- (Fig. 4e) and epifluorescence-imaged cells ( Fig. 4f and Supplementary Fig. 4) . Furthermore, pretreatment with a lower concentration of VK-II-86 (0.3 µM) for a longer period of time (3 h) also significantly inhibited the occurrence (P < 0.01) and frequency (P < 0.05) of SOICR (Fig. 4g) .
Notably, VK-II-86 also modified the function of both single native and purified recombinant RyR2 channels. Like carvedilol, it reduced the duration (P < 0.01) and increased the frequency (P < 0.01) of channel openings ( Fig. 4h and Supplementary Fig. 6 ). It also reduced intraburst event duration and increased intraburst event frequency (Supplementary Fig. 1 ). Thus, VK-II-86 is a minimally beta-blocking carvedilol analog with anti-SOICR activity.
Effect of new carvedilol analogs on CPVT
We next determined whether the SOICR-inhibiting carvedilol analogs with minimal beta blocking activity are effective in suppressing CPVT. We used mice heterozygous for the RyR2 R4496C mutation, which develop SOICR-driven CPVT [24] [25] [26] . In these mice (unlike their WT littermates), long-lasting ventricular tachyarrhythmias, including bidirectional ventricular tachyarrhythmias, can be evoked pharmacologically using caffeine and epinephrine ( Fig. 5a-d) . Notably, VK-II-86 suppressed CPVT in mice heterozygous for the RyR2 R4496C mutation in a dose-dependent manner (Fig. 5e,f and Supplementary  Fig. 7) . At 3.4 mg per kg body weight per day, VK-II-86 reduced the duration of ventricular tachyarrhythmias by 99.9% (P < 0.01) without adversely lowering the heart rate (8%, P = 0.08; Figs. 4c and 5f), whereas carvedilol (1.6 mg per kg body weight per day) reduced the duration of ventricular tachyarrhythmias by 79% (P < 0.01) and the heart rate by 36% (P < 0.05; Figs. 4c and 5f). We also determined the acute effect after treatment of VK-II-86 on ventricular tachyarrhythmias in mice homozygous for the RyR2 R4496C mutation treated with caffeine and epinephrine (Fig. 5g) . When injected with the vehicle DMSO, these mice showed ventricular tachyarrhythmias for >30 min. Treatment with either VK-II-86 (3.4 mg per kg body weight) or carvedilol (1.6 mg per kg body weight) completely abolished these ventricular tachyarrhythmias. Carvedilol was more effective than VK-II-86 (1.7 mg per kg body weight), probably owing to carvedilol's beta-blocking activity, which would reduce the strength of the original epinephrine trigger.
Combined SOICR inhibition and beta blockade
We used metoprolol or bisoprolol as a selective beta blocker and VK-II-86 as a SOICR inhibitor to test the premise that higher antiarrhythmic efficacy can be achieved by both SOICR inhibition and beta blockade compared to SOICR inhibition or beta blockade alone. Treatment of mice heterozygous for the RyR2 R4496C mutation with VK-II-86 plus metoprolol or with VK-II-86 plus bisoprolol was much more effective in preventing CPVT than was treatment with VK-II-86 (P < 0.01), metoprolol (P < 0.01), bisoprolol (P < 0.05; Fig. 5h and Supplementary Fig. 8 ) or propranolol (P < 0.05; Supplementary  Fig. 9 ) alone. These data show that the combination of SOICR inhibition and beta blockade increases antiarrhythmic efficacy.
We also generated two additional carvedilol analogs (CS-I-34 and CS-I-59; Fig. 6a) . Like VK-II-86, CS-I-34 and CS-I-59 had no effect on isoproterenol-enhanced heart rate (Fig. 6b) or the nonstimulated heart rate (Fig. 6c) . CS-I-34 and CS-I-59 reduced the occurrence and frequency of SOICR in cardiomyocytes (P < 0.01; Fig. 6d ) and suppressed SOICR in HEK293 cells (Fig. 6e) . CS-I-34 and CS-I-59 also significantly reduced the duration of ventricular tachyarrhythmias in mice heterozygous for the RyR2 R4496C mutation ( Fig. 6f ; P < 0.01). We also found that flecainide, a Na + channel blocker that has been shown to reduce the duration of RyR2 channel openings inhibited SOICR frequency and suppressed CPVT in mice heterozygous for the RyR2 R4496C mutation (Supplementary Fig. 10) , consistent with an earlier study 36 .
DISCUSSION
Carvedilol is the beta blocker of choice in preventing ventricular tachyarrhythmias and cardiovascular mortality in patients with heart failure [5] [6] [7] . Yet the mechanism underlying the antiarrhythmic benefit of carvedilol is not well defined. In this study, we tested the action of 14 known beta blockers on SOICR, and found that only carvedilol effectively inhibited SOICR. Because SOICR and SOICR-induced DADs are common in failing hearts 12, 13, 30, 31 , the unique anti-SOICR activity of carvedilol among beta blockers probably contributes to its favorable antiarrhythmic effect.
How does carvedilol suppress arrhythmogenic SOICR? Using single-channel recordings in lipid bilayers, we found that carvedilol directly modifies the gating properties of RyR2 by reducing the duration and increasing the frequency of channel openings. Reducing the duration of RyR2 channel openings is also the underlying mechanism by which flecainide suppresses SOICR and prevents SOICR-evoked CPVT in both mice and humans [36] [37] [38] . Thus, it seems that reducing RyR2-open duration is not only common to both drugs (carvedilol and flecainide) but also an effective means to suppress SOICR and SOICR-evoked ventricular tachyarrhythmias. However, flecainide is contraindicated in patients with previous myocardial infarction or substantial left ventricular dysfunction because of the risk of ventricular tachyarrhythmias 39 . Carvedilol also suppresses sarcoplasmic reticulum 'Ca 2+ leak' by reducing RyR2 phosphorylation or oxidation via its beta-blocking and antioxidant activities 40, 41 . These pathways of modulating sarcoplasmic reticulum Ca 2+ leak, however, are not carvedilol specific. In contrast, the unique anti-SOICR activity of carvedilol arises from a direct action on the RyR2 channel and is independent of the drug's beta-blocking and antioxidant activities. Thus, it is mechanistically different from those pathways described in earlier studies 40, 41 .
Is the unique anti-SOICR activity of carvedilol clinically relevant? The peak plasma concentration of carvedilol at therapeutic doses is ~100 ng ml −1 , with >98% of this bound to plasma proteins 34, 35 . Despite its high plasma protein association, carvedilol has a large volume of distribution (132 l) 34 , indicating that it accumulates over time in extravascular tissues such as cardiac muscle 42 . This accumulation is probably due to its high degree of lipophilicity 8, 43 . In line with this view, the concentrations of carvedilol in the heart are five-to sevenfold higher than those in the plasma 44, 45 . In addition, we found that with longer drug exposure, lower concentrations of carvedilol were able to suppress SOICR. Thus, carvedilol at therapeutic doses may accumulate in cardiac cells to a concentration that can modify the function of RyR2.
Carvedilol, with both beta-blocking and anti-SOICR activities, has the capability of suppressing both the stress-induced sarcoplasmic reticulum Ca 2+ overload that triggers SOICR and the SOICR itself. This dual action of carvedilol probably contributes to its favorable antiarrhythmic effect. However, the concentrations of carvedilol required to suppress SOICR (0.3-1 µM) are much higher than those required for beta blockade (~1 nM) 46 . Therefore, strong SOICR inhibition would require high doses of carvedilol, which could produce excessive beta blockade and accompanying adverse effects such as bradycardia 47 . In other words, the anti-SOICR benefit of carvedilol is dose limited by its beta-blocking activity. By synthesizing several carvedilol analogs with structural changes in regions thought to be essential for beta blockade, we pharmacologically separated the betablocking and anti-SOICR activities of carvedilol, so that the benefits of beta blocking and SOICR inhibition could be individually and optimally titrated. Three carvedilol analogs, VK-II-86, CS-I-34 and CS-I-59, exhibited minimal beta-blocking activity, but retained the ability to suppress SOICR. These new agents prevented CPVT in mice without causing bradycardia. We also showed that VK-II-86, when combined with selective beta blockers (metoprolol or bisoprolol), is more effective than VK-II-86, metoprolol or bisoprolol alone in suppressing ventricular tachyarrhytmias. Thus, SOICR inhibition combined with selective beta blockade represents a new and promising approach for better preventing Ca 2+ -mediated cardiac arrhythmias.
Carvedilol is a pleiotropic agent with diverse actions 5, 6, [48] [49] [50] [51] . Although our new carvedilol analogs lack beta-blocking activity, they may have other actions in addition to the anti-SOICR activity demonstrated here. Given the important role of SOICR in arrhythmogenesis, however, their anti-SOICR activity probably has a key role in their antiarrhythmic action. 
ONLINE METHODS
Single-cell Ca 2+ imaging of HEK293 cells. We used HEK293 cells expressing a CPVT-causing RyR2 mutant, R4496C 15, 16 , to assess the impact of beta blockers and other reagents on SOICR . We used single-cell Ca 2+ imaging as previously described 15, 16 .
Generation of knock-in mouse model harboring the CPVT RyR2 mutation R4496C. Detailed experimental procedures for the generation of the RyR2 R4496C-mutant mice are available in the Supplementary Methods.
Single-cell Ca 2+ imaging of mouse ventricular cardiomyocytes. Ca 2+ waves in freshly isolated ventricular cardiomyocytes were measured using single-cell Ca 2+ imaging as previously described 52 .
Confocal imaging. Laser scanning confocal imaging of Ca 2+ dynamics was carried out as previously described 53 .
Synthesis of carvedilol analogs. Detailed experimental procedures and characterization of new compounds are described in the Supplementary Methods.
Animal studies. Adult R4496C-mutant mice generated in this study and WT control littermates (2-4 months old) were used for all experiments. All animal studies were approved by the Institutional Animal Care and Use Committees at the University of Calgary and were carried out in accordance with US National Institutes of Health guidelines.
Electrocardiogram recordings in anesthetized mice. The effects of drugs on ventricular tachycardias provoked by epinephrine and caffeine were studied in anesthetized R4496C-mutant mice. Briefly, mice were lightly anesthetized with isoflurane vapor (0.5-1%). Anesthetized mice were placed on a heating pad (28 °C) and subcutaneous needle electrodes were applied to the left, right upper limb and right lower limb for ECG recording (BIOPAC MP System). Baseline ECG was recorded for 5 min, followed by the intraperitoneal injection of epinephrine (1.6 mg per kg body weight) and caffeine (120 mg per kg body weight). ECG was then continuously recorded for another 30 min. ECG recordings were analyzed using the AcqKnowledge 3.9.1 program (BIOPAC).
Drug tests in RyR2 R4496C-mutant mice. Epinephrine (1.6 mg per kg body weight) and caffeine (120 mg per kg body weight) challenge was carried out twice in the same R4496C-heterozygous mouse at an interval of 7 d. An ECG recording was obtained from all mice before any drug treatment as the baseline. Mice were then randomized into different groups and treated with various drugs by intraperitoneal injection for 5 d. The final dose of drug was administered 30 min before the second ECG test. The percentage of time that the mice were in ventricular tachycardia within the 30-min recording period in both the first and second ECG tests was determined and compared. To evaluate the acute effect of different drugs on CPVT, R4496C-homozygous mutant mice, continuously monitored with ECG recordings, were intraperitoneally injected with epinephrine (1.6 mg per kg body weight) and caffeine (120 mg per kg body weight) to induce ventricular tachycardia. One dose of each drug tested was then intraperitoneally injected into the mice 12 min after the injection of epinephrine and caffeine. ECG was continuously recorded for an additional 21 min.
Statistical analyses.
All values shown are means ± s.e.m. unless indicated otherwise. To test for differences between groups, we used two-tailed Student's t test or one-way analysis of variance with post hoc test. Statistical analyses were carried out using SPSS V.15.0 (SPSS). P < 0.05 was considered significant. 
Additional methods. Detailed methodology is described in
